Medicus Pharma reported that its Phase 2 SKNJCT‑003 study of the dissolvable microneedle array (D‑MNA) achieved a 73 % clinical clearance rate in the 200 µg dose cohort, with 40 % histological clearance confirmed by biopsy, among 90 patients with nodular basal cell carcinoma.
The study also showed a 42 % clinical clearance rate at Day 57 in the 100 µg dose cohort, underscoring a clear dose‑response relationship. The 73 % figure applies to the 200 µg cohort at Day 57, not Day 29, and represents sustained biological activity over the 57‑day observation period.
"We are extremely encouraged by these topline results, which not only validate management’s scientific and investment thesis, but also provide what we consider to be decision‑grade evidence of clinical activity, particularly at the 200‑microgram dose level," said Dr. Raza Bokhari, Executive Chairman and CEO.
"The observed increase in clearance rates at Day 57 in the higher‑dose cohort reinforces the sustained biological activity of SkinJect and supports advancement into the next stage of development. Importantly, we believe this dataset strengthens our position in ongoing and prospective partnering discussions and may accelerate strategic engagement as we evaluate optimal pathways for value creation," Dr. Bokhari added.
Medicus Pharma’s financial profile remains constrained, with a limited cash runway, negative equity, and a high cash burn that has forced the company to pursue capital raises. The company’s ability to fund future development and operations depends on securing additional financing or a partnership that can provide a commercial pathway.
The Phase 2 results constitute decision‑grade evidence that could support an end‑of‑phase meeting with the U.S. Food and Drug Administration in the first half of 2026 and may open the door to strategic collaborations. However, the company’s financial fragility means that the clinical success must be coupled with a clear plan to secure resources and a viable commercialization strategy to translate the data into a sustainable business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.